Skip to main content

Table 3 Events related to treatment with gemfibrozil

From: Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders

 

Causal relationship

Causal relationship

Probable

Not established

General:

weight loss

 

Cardiac

extrasystoles

 

Gastrointestinal

cholestatic jaundice

pancreatitis

 

hepatoma

 

colitis

Central Nervous System

dizziness

confusion

Somnolence

convulsions

Paresthesia

syncope

peripheral neuritis

 

decreased libido

 

depression

 

headache

 

Eye

blurred vision

retina edema

Genitourinary

impotence

decreased male fertility

 

renal dysfunction

Musculoskeletal

myopathy

 

myasthenia

 

myalgia

 

painful extremities

 

arthralgia

 

synovitis

 

rhabdomyolysis

 

Clinical Laboratories

increased creatine

positive antinuclear antibody

Phosphokinase

 

increased bilirubin

 

increased liver

 

transaminases (AST, ALT)

 

increased alkaline

 

phosphatase

 

Hematopoietic

anemia

thrombocytopenia

leukopenia

 

bone marrow hypoplasia

 

eosinophilia

 

Immunologic

angioedema

anaphylaxis

laryngeal edema

Lupus-like syndrome

urticarial

vasculitis

Integumentary

exfoliative dermatitis

alopecia

Rash

photosensitivity

dermatitis

 

pruritus

 
  1. SPC (Standard of Product Characteristics) of LOPID® (Gemfibrozil Tablets, USP) by Pfizer, Revised March 2016